Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10556877 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2TAAR1PTGER4PTGER3 | |
| SCHEMBL10556870 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2TAAR1PTGER4PTGER3 | |
| SCHEMBL17160012 | 0.79 | GABRA1 (0.45) | GABRA1GABRB2PTGER4PTGER3PTGER2 | |
| SCHEMBL31348024 | 0.79 | GABRA1 (0.45) | GABRA1GABRB2PTGER4PTGER3PTGER2 | |
| SCHEMBL17155197 | 0.79 | PTGER3 (0.37) | GABRA1GABRB2TAAR1PTGER4PTGER3 | |
| SCHEMBL17154235 | 0.77 | PNMT (0.33) | GABRA1GABRB2HTR2ASLC6A2SLC6A4 | |
| SCHEMBL8120563 | 0.77 | GABRA1 (0.50) | GABRA1GABRB2TAAR1MAOASLC6A2 | |
| SCHEMBL6546293 | 0.76 | NFE2L2 (0.46) | GABRA1GABRB2HTR2APTGER4PTGER3 | |
| SCHEMBL6546294 | 0.76 | NFE2L2 (0.46) | GABRA1GABRB2HTR2APTGER4PTGER3 | |
| SCHEMBL16105670 | 0.76 | NFE2L2 (0.46) | GABRA1GABRB2HTR2APTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388179-B2 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284389-A1 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, SCN1A, SCN2B | GABRA1 297/4885GABRB2 279/4885TAAR1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.